Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Deloitte
Medtronic
McKesson
Novartis
Accenture
Colorcon
Argus Health
Chinese Patent Office

Generated: January 19, 2018

DrugPatentWatch Database Preview

SANCTURA Drug Profile

« Back to Dashboard

Which patents cover Sanctura, and what generic alternatives are available?

Sanctura is a drug marketed by Allergan and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SANCTURA is trospium chloride. There are sixteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
Summary for SANCTURA
Drug patent expirations by year for SANCTURA

US Patents and Regulatory Information for SANCTURA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SANCTURA trospium chloride TABLET;ORAL 021595-001 May 28, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SANCTURA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 3/2/2009

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
Teva
QuintilesIMS
Citi
Mallinckrodt
Harvard Business School
Healthtrust
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot